PTPN11 and metabolic dysfunction-associated steatohepatitis: Specifically, the major findings of this study include that (a) pharmacologic inhibition of SHP2 activates YAP and accelerates liver regeneration following partial hepatectomy in mice; (b) SHP2 inhibition results in transcriptional changes associated with pro-proliferative and metabolic signaling pathways; and (c) SHP2 inhibition improves survival in a NASH partial hepatectomy model.